Skip to main content

Table 5 Enrollment and outcomes in studies using Pritchard or Zuspan, or any Dhaka regimen

From: An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management

 

Enrollment N

Outcomes N (%)

Study

Subjects

Pre-eclampsia

Eclampsia

Affected patella reflex

Respiratory depression

Oliguria

Skipped dose

Calcium gluconate

Maternal death

All

Due to MgSO4

PRITCHARD OR ZUSPAN

Altman 1

5055

5055

0

59 4

514

114

1875

14

11

0

Eclampsia Collab. Trial A 2

453

0

453

 

35

   

17

 

Eclampsia Collab. Trial B 3

388

0

388

 

32

   

10

 

TOTAL

5896

5055

841

59 (1.0)

118 (2.0)

114 (1.9)

187 (3.2)

14 (0.2)

38 (0.6)

0 (0)

DHAKA (ALL)

Begum

65

0

65

5

0

0

  

0

0

Shilva

25

0

25

8

 

5

137

 

0

0

Shilva 6

25

0

25

2

 

1

38

 

0

0

TOTAL

115

0

115

15 (13)

0 (0)

6 (5.2)

16 (13.9)

0 (0)

0 (0)

0 (0)

  1. 1 Subjects received either Pritchard or Zuspan regimen; 2 Study of Pritchard or Zuspan regimen vs diazepam; 3 Study of Pritchard or Zuspan regimen vs phenytoin; 4 4 Women had respiratory depression and absent tendon reflex; 5 Includes 114 women who stopped treatment because of oliguria or renal failure, 26 women who stopped treatment because of respiratory depression or arrest, and 47 women who stopped treatment because of absent tendon reflex; 6 Received Dhaka modified regimen; 7 8 Skipped because loss of knee-jerk and 5 because of oliguria; 8 2 Skipped because loss of knee-jerk and 1 because of oliguria.
Back to article page

BMC Pregnancy and Childbirth

ISSN: 1471-2393

Contact us